These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

70 related articles for article (PubMed ID: 24461121)

  • 1. Linagliptin for elderly patients with type 2 diabetes.
    Shah R
    Lancet; 2014 Jan; 383(9914):306-7. PubMed ID: 24461121
    [No Abstract]   [Full Text] [Related]  

  • 2. Linagliptin for elderly patients with type 2 diabetes.
    Salvo F; Moore N; Pariente A
    Lancet; 2014 Jan; 383(9914):307. PubMed ID: 24461122
    [No Abstract]   [Full Text] [Related]  

  • 3. Linagliptin for elderly patients with type 2 diabetes.
    Yamada T
    Lancet; 2014 Jan; 383(9914):306. PubMed ID: 24461120
    [No Abstract]   [Full Text] [Related]  

  • 4. Linagliptin for elderly patients with type 2 diabetes - Authors' reply.
    Barnett AH; von Eynatten M; Patel S; Woerle HJ
    Lancet; 2014 Jan; 383(9914):307-8. PubMed ID: 24461123
    [No Abstract]   [Full Text] [Related]  

  • 5. Frailty and diabetes.
    Sinclair A; Morley J
    Lancet; 2013 Oct; 382(9902):1386-7. PubMed ID: 23948126
    [No Abstract]   [Full Text] [Related]  

  • 6. [Oral Linagliptin (Trajenta)].
    Duh D; Tanret I
    J Pharm Belg; 2013 Mar; (1):41-3. PubMed ID: 23638612
    [No Abstract]   [Full Text] [Related]  

  • 7. Diabetes: Add-on to metformin in T2DM--linagliptin or glimepiride?
    Christensen M; Knop FK
    Nat Rev Endocrinol; 2012 Oct; 8(10):576-8. PubMed ID: 22926098
    [No Abstract]   [Full Text] [Related]  

  • 8. [Pharmacological and clinical profiles of the DPP-4 inhibitor linagliptin (Trazenta)].
    Ohmura T; Hayashi N; Encinas J
    Nihon Yakurigaku Zasshi; 2012 Apr; 139(4):174-83. PubMed ID: 22498683
    [No Abstract]   [Full Text] [Related]  

  • 9. Linagliptin and newer DPP-4 inhibitors: newer uses and newer indications.
    Kalra S; Unnikrishnan AG; Agrawal N; Singh AK
    Recent Pat Endocr Metab Immune Drug Discov; 2011 Sep; 5(3):197-202. PubMed ID: 21913883
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Linagliptin approved for type 2 diabetes.
    Traynor K
    Am J Health Syst Pharm; 2011 Jun; 68(12):1059. PubMed ID: 21642558
    [No Abstract]   [Full Text] [Related]  

  • 11. Linagliptin, a dipeptidyl peptidase-4 inhibitor with a unique pharmacological profile, and efficacy in a broad range of patients with type 2 diabetes.
    Forst T; Pfützner A
    Expert Opin Pharmacother; 2012 Jan; 13(1):101-10. PubMed ID: 22149370
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Linagliptin: a new DPP-4 inhibitor for the treatment of type 2 diabetes mellitus.
    Toth PP
    Postgrad Med; 2011 Jul; 123(4):46-53. PubMed ID: 21680988
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Linagliptin, a xanthine-based dipeptidyl peptidase-4 inhibitor, decreases serum uric acid levels in type 2 diabetic patients partly by suppressing xanthine oxidase activity.
    Yamagishi S; Ishibashi Y; Ojima A; Sugiura T; Matsui T
    Int J Cardiol; 2014 Sep; 176(2):550-2. PubMed ID: 25065332
    [No Abstract]   [Full Text] [Related]  

  • 14. Kidney Disease End Points in a Pooled Analysis of Individual Patient-Level Data From a Large Clinical Trials Program of the Dipeptidyl Peptidase 4 Inhibitor Linagliptin in Type 2 Diabetes.
    Cooper ME; Perkovic V; McGill JB; Groop PH; Wanner C; Rosenstock J; Hehnke U; Woerle HJ; von Eynatten M
    Am J Kidney Dis; 2015 Sep; 66(3):441-9. PubMed ID: 25960304
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Jentadueto XR for type 2 diabetes.
    Med Lett Drugs Ther; 2016 Aug; 58(1500):98-100. PubMed ID: 27466749
    [No Abstract]   [Full Text] [Related]  

  • 16. Linagliptin for the treatment of type 2 diabetes mellitus: a drug safety evaluation.
    Barnett AH
    Expert Opin Drug Saf; 2015 Jan; 14(1):149-59. PubMed ID: 25351273
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and tolerability of linagliptin: a pooled analysis of data from randomized controlled trials in 3572 patients with type 2 diabetes mellitus.
    Schernthaner G; Barnett AH; Emser A; Patel S; Troost J; Woerle HJ; von Eynatten M
    Diabetes Obes Metab; 2012 May; 14(5):470-8. PubMed ID: 22268497
    [TBL] [Abstract][Full Text] [Related]  

  • 18. DPP-4 inhibition and neuroprotection: do mechanisms matter?
    Shannon RP
    Diabetes; 2013 Apr; 62(4):1029-31. PubMed ID: 23520281
    [No Abstract]   [Full Text] [Related]  

  • 19. Single-pill combination therapy for type 2 diabetes mellitus: linagliptin plus empagliflozin.
    Aronson R
    Curr Med Res Opin; 2015 May; 31(5):901-11. PubMed ID: 25775379
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use of the dipeptidyl peptidase-4 inhibitor linagliptin in combination therapy for type 2 diabetes.
    Lajara R
    Expert Opin Pharmacother; 2012 Dec; 13(18):2663-71. PubMed ID: 23137412
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.